
Virgil A S H Dalm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/452361/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Somatostatin receptors in malignant lymphomas: targets for radiotherapy?. Journal of Nuclear Medicine, 2004, 45, 8-16.	5.0	166
2	Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. American Journal of Physiology - Endocrinology and Metabolism, 2003, 285, E344-E353.	3.5	154
3	Reviewing primary Sjögren's syndrome: beyond the dryness - From pathophysiology to diagnosis and treatment. International Journal of Medical Sciences, 2017, 14, 191-200.	2.5	148
4	Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming. New England Journal of Medicine, 2022, 386, 951-963.	27.0	102
5	Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000782.	3.8	91
6	Primary immunodeficiencies in the Netherlands: National patient data demonstrate the increased risk of malignancy. Clinical Immunology, 2015, 156, 154-162.	3.2	80
7	Genetic defects in PI3KĨ´affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections. Clinical Immunology, 2017, 176, 77-86.	3.2	80
8	Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis. PLoS ONE, 2019, 14, e0223897.	2.5	70
9	Distribution pattern of somatostatin and cortistatin mRNA in human central and peripheral tissues. Clinical Endocrinology, 2004, 60, 625-629.	2.4	66
10	TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis. Journal of Autoimmunity, 2018, 91, 97-102.	6.5	58
11	Exhaustion of the CD8+ T Cell Compartment in Patients with Mutations in Phosphoinositide 3-Kinase Delta. Frontiers in Immunology, 2018, 9, 446.	4.8	52
12	Azacytidine Treatment for VEXAS Syndrome. HemaSphere, 2021, 5, e661.	2.7	45
13	Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardiâ€Goutières Syndrome, a Type I Interferonopathy. Arthritis and Rheumatology, 2019, 71, 829-831.	5.6	41
14	Prevalence of distal renal tubular acidosis in primary Sjögren's syndrome. Rheumatology, 2015, 54, 933-939.	1.9	40
15	A Novel Heterozygous Mutation in the STAT1 SH2 Domain Causes Chronic Mucocutaneous Candidiasis, Atypically Diverse Infections, Autoimmunity, and Impaired Cytokine Regulation. Frontiers in Immunology, 2017, 8, 274.	4.8	40
16	The medically immunocompromised adult traveler and pre-travel counseling: Status quo 2014. Travel Medicine and Infectious Disease, 2014, 12, 219-228.	3.0	37
17	Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1). Journal of Allergy and Clinical Immunology, 2018, 142, 328-330.e2.	2.9	35
18	Determinants of Serum Immunoglobulin Levels: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2021, 12, 664526.	4.8	35

VIRGIL A S H DALM

#	Article	IF	CITATIONS
19	Hyperâ€lgE in the allergy clinic––when is it primary immunodeficiency?. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2122-2136.	5.7	34
20	Human autoinflammatory disease reveals ELF4 as a transcriptional regulator of inflammation. Nature Immunology, 2021, 22, 1118-1126.	14.5	30
21	The 11q Terminal Deletion Disorder Jacobsen Syndrome is a Syndromic Primary Immunodeficiency. Journal of Clinical Immunology, 2015, 35, 761-768.	3.8	25
22	Basic FGF and PDGF-BB synergistically stimulate hyaluronan and IL-6 production by orbital fibroblasts. Molecular and Cellular Endocrinology, 2016, 433, 94-104.	3.2	24
23	Platelet-Derived Growth Factor-BB Enhances Adipogenesis in Orbital Fibroblasts. , 2015, 56, 5457.		23
24	Rapid Low-Cost Microarray-Based Genotyping for Genetic Screening in Primary Immunodeficiency. Frontiers in Immunology, 2020, 11, 614.	4.8	21
25	Strategies for B-Cell Receptor Repertoire Analysis in Primary Immunodeficiencies: From Severe Combined Immunodeficiency to Common Variable Immunodeficiency. Frontiers in Immunology, 2015, 6, 157.	4.8	20
26	Uveitis causes according to immune status of patients. Acta Ophthalmologica, 2019, 97, 53-59.	1.1	13
27	Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol. Frontiers in Immunology, 2021, 12, 753319.	4.8	13
28	Clinical and In Vitro Evidence Favoring Immunoglobulin Treatment of a Chronic Norovirus Infection in a Patient With Common Variable Immunodeficiency. Journal of Infectious Diseases, 2022, 226, 1781-1789.	4.0	12
29	MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis. Rheumatology, 2019, 58, 1302-1303.	1.9	11
30	Integrative Analysis of Proteomics and DNA Methylation in Orbital Fibroblasts From Graves' Ophthalmopathy. Frontiers in Endocrinology, 2020, 11, 619989.	3.5	11
31	Outcomes of Systemic Treatment in Children and Adults With Netherton Syndrome: A Systematic Review. Frontiers in Immunology, 2022, 13, 864449.	4.8	11
32	Yellow fever vaccination for immunocompromised travellers: unjustified vaccination hesitancy?. Journal of Travel Medicine, 2019, 26, .	3.0	10
33	What Works When Treating Granulomatous Disease in Genetically Undefined CVID? A Systematic Review. Frontiers in Immunology, 2020, 11, 606389.	4.8	10
34	Histamine induces NF-κB controlled cytokine secretion by orbital fibroblasts via histamine receptor type-1. Experimental Eye Research, 2016, 147, 85-93.	2.6	9
35	MPO-ANCA associated vasculitis with mononeuritis multiplex following influenza vaccination. Allergy, Asthma and Clinical Immunology, 2017, 13, 49.	2.0	9
36	Soluble Interleukin-2 Receptor Is a Promising Serum Biomarker for Granulomatous Disease in Common Variable Immune Deficiency. Journal of Clinical Immunology, 2021, 41, 694-697.	3.8	9

VIRGIL A S H DALM

#	Article	IF	CITATIONS
37	Endocrine Disorders Are Prominent Clinical Features in Patients With Primary Antibody Deficiencies. Frontiers in Immunology, 2019, 10, 2079.	4.8	8
38	MicroRNA-378a-3p is overexpressed in psoriasis and modulates cell cycle arrest in keratinocytes via targeting BMP2 gene. Scientific Reports, 2021, 11, 14186.	3.3	8
39	Inflammatory bowel disease in primary immunodeficiency disorders is a heterogeneous clinical entity requiring an individualized treatment strategy: A systematic review. Autoimmunity Reviews, 2021, 20, 102872.	5.8	7
40	Psychological Symptoms in Primary Immunodeficiencies: a Common Comorbidity?. Journal of Clinical Immunology, 2022, 42, 695-698.	3.8	7
41	Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers. Clinical Infectious Diseases, 2023, 76, e533-e536.	5.8	7
42	Determinants and Clinical Implications of Thyroid Peroxidase Antibodies in Middle-Aged and Elderly Individuals: The Rotterdam Study. Thyroid, 2021, , .	4.5	6
43	Thymosin α1: a novel therapeutic option for patients with refractory chronic purulent rhinosinusitis. Annals of the New York Academy of Sciences, 2012, 1270, 1-7.	3.8	4
44	Graves' orbitopathy: the ongoing search for new treatment strategies. Lancet Diabetes and Endocrinology,the, 2018, 6, 261-263.	11.4	4
45	Activated PI3Kδ syndrome, an immunodeficiency disorder, leads to sensorimotor deficits recapitulated in a murine model. Brain, Behavior, & Immunity - Health, 2021, 18, 100377.	2.5	4
46	Clinical features and immune-related protein patterns of anti-MDA5 positive clinically amyopathic dermatomyositis Dutch patients. Rheumatology, 2022, 61, 4087-4096.	1.9	4
47	Blood myxovirus resistance proteinâ€1 measurement in the diagnostic workâ€up of suspected COVIDâ€19 infection in the emergency department. Immunity, Inflammation and Disease, 2022, 10, e609.	2.7	4
48	Three patients with defects in interferon gamma receptor signaling: A challenging diagnosis. Pediatric Allergy and Immunology, 2022, 33, e13768.	2.6	2
49	Patients with Chromosome 11q Deletions Are Characterized by Inborn Errors of Immunity Involving both B and T Lymphocytes. Journal of Clinical Immunology, 0, , .	3.8	1
50	Jacobsen Syndrome. , 2019, , 1-5.		0
51	Jacobsen Syndrome. , 2020, , 413-417.		Ο
52	Title is missing!. , 2019, 14, e0223897.		0
53	Title is missing!. , 2019, 14, e0223897.		0
54	Title is missing!. , 2019, 14, e0223897.		0

4

#	Article	IF	CITATIONS
55	Title is missing!. , 2019, 14, e0223897.		0